Last reviewed · How we verify
Tamsulosin and solifenacin
At a glance
| Generic name | Tamsulosin and solifenacin |
|---|---|
| Also known as | Harnal-D and Vesicare tablet |
| Sponsor | Jeil Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Dry Mouth
- Constipation
- Dry mouth
Key clinical trials
- Study of Tamsulosin, Solifenacin and Mirabegron in Alleviating Ureteral Stent-related Symptoms (PHASE3)
- Comparing Tamsulosin and Solifenacin for Relieving Double J Stent Symptoms: Using the USSQ. (PHASE4)
- Single Dose Versus Double Dose Tamsulosin 0.4 and Solifenacin 5 in Management of Stent Related Symptoms (NA)
- Real World Study in Greek Patients with BPH for Disease Control and QoL Under FDC Treatment with Solifenacin/Tamsulosin.
- Long Term Study of Solifenacin Succinate and Tamsulosin Hydrochloride Oral Controlled Absorption System (OCAS) in Males With Lower Urinary Tract Symptoms (PHASE3)
- Study of Solifenacin Succinate and Tamsulosin Hydrochloride OCAS in Males With Lower Urinary Tract Symptoms (PHASE3)
- Efficacy of Tadalafil/Solifenacin VS Tamsulosin/Solifenacin Combination Therapy for BPH/OAB (PHASE4)
- Clinical Trial to Compare the Solifenacin/Tamsulosin Combination Therapy With Tamsulosin Monotherapy for LUTS Due to BPH (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tamsulosin and solifenacin CI brief — competitive landscape report
- Tamsulosin and solifenacin updates RSS · CI watch RSS
- Jeil Pharmaceutical Co., Ltd. portfolio CI